These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17919137)

  • 1. The European LABDEL project and its relevance to the prevention and treatment of allergies.
    Daniel C; Repa A; Mercenier A; Wiedermann U; Wells J
    Allergy; 2007 Nov; 62(11):1237-42. PubMed ID: 17919137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1.
    Daniel C; Repa A; Wild C; Pollak A; Pot B; Breiteneder H; Wiedermann U; Mercenier A
    Allergy; 2006 Jul; 61(7):812-9. PubMed ID: 16792578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization.
    Schwarzer M; Repa A; Daniel C; Schabussova I; Hrncir T; Pot B; Stepankova R; Hudcovic T; Pollak A; Tlaskalova-Hogenova H; Wiedermann U; Kozakova H
    Allergy; 2011 Mar; 66(3):368-75. PubMed ID: 20880132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
    Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
    Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination.
    Focke M; Linhart B; Hartl A; Wiedermann U; Sperr WR; Valent P; Thalhamer J; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Oct; 34(10):1525-33. PubMed ID: 15479266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities.
    Wild C; Wallner M; Hufnagl K; Fuchs H; Hoffmann-Sommergruber K; Breiteneder H; Scheiner O; Ferreira F; Wiedermann U
    Allergy; 2007 Jan; 62(1):33-41. PubMed ID: 17156339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hitting the mucosal road in tolerance induction.
    Wiedermann U
    Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():63-72; discussion 72-74, 251-7. PubMed ID: 19710515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.
    Repa A; Grangette C; Daniel C; Hochreiter R; Hoffmann-Sommergruber K; Thalhamer J; Kraft D; Breiteneder H; Mercenier A; Wiedermann U
    Vaccine; 2003 Dec; 22(1):87-95. PubMed ID: 14604575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora.
    Repa A; Kozakova H; Hudcovic T; Stepankova R; Hrncir T; Tlaskalova-Hogenova H; Pollak A; Wiedermann U
    Immunol Lett; 2008 Apr; 117(1):50-6. PubMed ID: 18241932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria.
    Hisbergues M; Magi M; Rigaux P; Steuve J; Garcia L; Goudercourt D; Pot B; Pestel J; Jacquet A
    Clin Exp Allergy; 2007 Sep; 37(9):1286-95. PubMed ID: 17845408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses.
    Bublin M; Hoflehner E; Wagner B; Radauer C; Wagner S; Hufnagl K; Allwardt D; Kundi M; Scheiner O; Wiedermann U; Breiteneder H
    Vaccine; 2007 Dec; 25(50):8395-404. PubMed ID: 17997199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy.
    Lund L; Henmar H; Würtzen PA; Lund G; Hjortskov N; Larsen JN
    Clin Exp Allergy; 2007 Apr; 37(4):564-71. PubMed ID: 17430354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy.
    Crameri R; Kündig TM; Akdis CA
    Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):568-73. PubMed ID: 19680120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.
    Winkler B; Hufnagl K; Spittler A; Ploder M; Kállay E; Vrtala S; Valenta R; Kundi M; Renz H; Wiedermann U
    Allergy; 2006 Feb; 61(2):173-80. PubMed ID: 16409192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular composition and biological activity of commercial birch pollen allergen extracts.
    Focke M; Marth K; Valenta R
    Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of probiotic bacteria for prevention and therapy of allergic diseases: studies in mouse model of allergic sensitization.
    Di Felice G; Barletta B; Butteroni C; Corinti S; Tinghino R; Colombo P; Boirivant M
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S130-2. PubMed ID: 18806704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual vaccines based on wild-type recombinant allergens.
    Van Overtvelt L; Razafindratsita A; St-Lu N; Didierlaurent A; Batard T; Lombardi V; Martin E; Moingeon P
    Eur Ann Allergy Clin Immunol; 2006 Sep; 38(7):247-9. PubMed ID: 17124785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome.
    Niederberger V; Reisinger J; Valent P; Krauth MT; Pauli G; van Hage M; Cromwell O; Horak F; Valenta R
    J Allergy Clin Immunol; 2007 Apr; 119(4):1013-6. PubMed ID: 17292956
    [No Abstract]   [Full Text] [Related]  

  • 20. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.